Literature DB >> 27664248

2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients.

F Roila1, A Molassiotis2, J Herrstedt3, M Aapro4, R J Gralla5, E Bruera6, R A Clark-Snow7, L L Dupuis8, L H Einhorn9, P Feyer10, P J Hesketh11, K Jordan12, I Olver13, B L Rapoport14, J Roscoe15, C H Ruhlmann3, D Walsh16, D Warr17, M van der Wetering18.   

Abstract

Entities:  

Year:  2016        PMID： 27664248     DOI： 10.1093/annonc/mdw270

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  160 in total

1.  Gastrointestinal symptoms are associated with trajectories of chemotherapy-induced nausea.

Authors:  Komal Singh; Kord M Kober; Steven M Paul; Marilyn Hammer; Fay Wright; Yvette P Conley; Jon D Levine; Christine Miaskowski
Journal:  Support Care Cancer       Date:  2019-08-19       Impact factor: 3.603

Review 2.  Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting.

Authors:  Hanno Riess; Cihan Ay; Rupert Bauersachs; Cecilia Becattini; Jan Beyer-Westendorf; Francis Cajfinger; Ian Chau; Alexander T Cohen; Alok A Khorana; Anthony Maraveyas; Marcos Renni; Annie M Young
Journal:  Oncologist       Date:  2018-04-12

3.  Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis.

Authors:  Ronald Chow; David G Warr; Rudolph M Navari; May Tsao; Marko Popovic; Leonard Chiu; Milica Milakovic; Henry Lam; Carlo DeAngelis
Journal:  Support Care Cancer       Date:  2018-05-23       Impact factor: 3.603

4.  Nausea and vomiting in palliative care.

Authors:  Charlotte Leach
Journal:  Clin Med (Lond)       Date:  2019-07       Impact factor: 2.659

5.  Emergency Department Visits for Emesis Following Chemotherapy: Guideline Nonadherence, OP-35, and a Path Back to the Future.

Authors:  Alfred I Neugut; Susan E Bates
Journal:  Oncologist       Date:  2021-03-04

Review 6.  Antiemetic therapy for non-anthracycline and cyclophosphamide moderately emetogenic chemotherapy.

Authors:  Naoki Inui
Journal:  Med Oncol       Date:  2017-04-01       Impact factor: 3.064

7.  Absorption, metabolism, and excretion of the antiemetic rolapitant, a selective neurokinin-1 receptor antagonist, in healthy male subjects.

Authors:  Zhi-Yi Zhang; Jing Wang; Vikram Kansra; Xiaodong Wang
Journal:  Invest New Drugs       Date:  2018-07-21       Impact factor: 3.850

Review 8.  Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-a systematic review and meta-analysis.

Authors:  Karin Jordan; Luisa Blättermann; Axel Hinke; Carsten Müller-Tidow; Franziska Jahn
Journal:  Support Care Cancer       Date:  2017-08-31       Impact factor: 3.603

9.  The timeliness of patients reporting the side effects of chemotherapy.

Authors:  Ian Olver; Mariko Carey; Allison Boyes; Alix Hall; Natasha Noble; Jamie Bryant; Justin Walsh; Rob Sanson-Fisher
Journal:  Support Care Cancer       Date:  2018-05-03       Impact factor: 3.603

10.  Risk factors of chemotherapy-induced nausea and vomiting in patients with metastatic colorectal cancer: a prospective cohort study (YCOG1301).

Authors:  Shogo Takei; Atsushi Ishibe; Jun Watanabe; Kazuteru Watanabe; Yusuke Suwa; Shinsuke Suzuki; Kazuya Nakagawa; Hirokazu Suwa; Mitsuyoshi Ota; Yasushi Ichikawa; Chikara Kunisaki; Takeharu Yamanaka; Itaru Endo
Journal:  Int J Colorectal Dis       Date:  2020-08-28       Impact factor: 2.571
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.